Breast- FABP1 negative invasive breast cancer of no special type (NST).
Breast- FABP1 negative invasive breast cancer of no special type (NST). Breast- FABP1 negative invasive lobular breast cancer.
Breast- FABP1 negative invasive lobular breast cancer. Colon- Colorectal adenocarcinoma with moderate to strong FABP1 immunostaining of >50% of tumor cells.
Colon- Colorectal adenocarcinoma with moderate to strong FABP1 immunostaining of >50% of tumor cells. Colon- Colorectal adenocarcinoma with very strong FABP1 immunostaining of tumor cells. Contamination (spill over) artifact leads to significant staining of adjacent tumor stroma.
Colon- Colorectal adenocarcinoma with very strong FABP1 immunostaining of tumor cells. Contamination (spill over) artifact leads to significant staining of adjacent tumor stroma. Colon- FABP1 negative colorectal adenocarcinoma.
Colon- FABP1 negative colorectal adenocarcinoma. Esophagus- Adenocarcinoma with focal moderate to strong FABP1 immunostaining of tumor cells.
Esophagus- Adenocarcinoma with focal moderate to strong FABP1 immunostaining of tumor cells. Kidney- Clear cell renal cell carcinoma with weak to moderate FABP1 immunostaining of about 30-40% of tumor cells.
Kidney- Clear cell renal cell carcinoma with weak to moderate FABP1 immunostaining of about 30-40% of tumor cells. Kidney- Papillary renal cell carcinoma with focal moderate FABP1 immunostaining of <5% of tumor cells.
Kidney- Papillary renal cell carcinoma with focal moderate FABP1 immunostaining of <5% of tumor cells. Lymph node- FABP1 negative Hodgkin’s lymphoma.
Lymph node- FABP1 negative Hodgkin’s lymphoma. Ovary- FABP1 negative clear cell carcinoma.
Ovary- FABP1 negative clear cell carcinoma. Ovary- FABP1 negative serous high-grade carcinoma.
Ovary- FABP1 negative serous high-grade carcinoma. Ovary- Mucinous carcinoma with strong FABP1 immunostaining of tumor cells.
Ovary- Mucinous carcinoma with strong FABP1 immunostaining of tumor cells. Pancreas- Adenocarcinoma of the papilla Vaterii with strong FABP1 immunostaining of >95% of tumor cells.
Pancreas- Adenocarcinoma of the papilla Vaterii with strong FABP1 immunostaining of >95% of tumor cells. Pancreas- Ductal adenocarcinoma with moderate FABP1 immunostaining of 5-10% of tumor cells.
Pancreas- Ductal adenocarcinoma with moderate FABP1 immunostaining of 5-10% of tumor cells. Pancreas- FABP1 negative ductal adenocarcinoma.
Pancreas- FABP1 negative ductal adenocarcinoma. Pancreas- FABP1 negative neuroendocrine tumor.
Pancreas- FABP1 negative neuroendocrine tumor. Penis- FABP1 negative squamous cell carcinoma.
Penis- FABP1 negative squamous cell carcinoma. Pharynx- FABP1 negative squamous cell carcinoma.
Pharynx- FABP1 negative squamous cell carcinoma. Prostate- FABP1 negative adenocarcinoma (Gleason 3+3=6).
Prostate- FABP1 negative adenocarcinoma (Gleason 3+3=6). Skin- FABP1 negative Merkel cell carcinoma.
Skin- FABP1 negative Merkel cell carcinoma. Soft tissue- FABP1 negative leiomyosarcoma.
Soft tissue- FABP1 negative leiomyosarcoma. Soft tissue- FABP1 negative liposarcoma.
Soft tissue- FABP1 negative liposarcoma. Stomach- FABP1 negative gastrointestinal stromal tumor (GIST).
Stomach- FABP1 negative gastrointestinal stromal tumor (GIST). Testis- FABP1 negative Leydig cell tumor.
Testis- FABP1 negative Leydig cell tumor. Testis- FABP1 negative seminoma.
Testis- FABP1 negative seminoma. Thyroid- FABP1 negative medullary carcinoma.
Thyroid- FABP1 negative medullary carcinoma. Thyroid- FABP1 negative papillary carcinoma.
Thyroid- FABP1 negative papillary carcinoma. Uterus- Endometrium carcinoma with very strong FABP1 immunostaining of tumor cells. Contamination (spill over) artifact leads to significant staining of adjacent tumor stroma.
Uterus- Endometrium carcinoma with very strong FABP1 immunostaining of tumor cells. Contamination (spill over) artifact leads to significant staining of adjacent tumor stroma. Vagina- FABP1 negative squamous cell carcinoma.
Vagina- FABP1 negative squamous cell carcinoma.